Generic drug maker Amneal has been slowly melting down since 2015, falling from $50 per share to today's closing price of $3.44. Amneal makes money, though it missed estimates last quarter by about $0.04 per share.
S&P Capital IQ rates it an undervalued, high quality, and financially healthy company, but I think that overstates the case. In my opinion this company is at real financial risk. Amneal's cash reserve shrank by 3/4 year-over-year, while its accounts receivable grew in an equal amount. That suggests that while Amneal's assets may look good on paper, it may not be very liquid. Amneal may need to do a better job with collections. Furthermore, ongoing litigation over price fixing and the opioid epidemic exposes Amneal to potential damages of $1.2 billion, almost its total current assets.
Amneal has some support at its current share price as it approaches lows from back in 2008 and 2002-2003. It also got an analyst upgrade today from SVB Leerink after the analytics firm determined that of the major generic drug makers, Amneal has the least exposure to that ongoing litigation I mentioned. (Endo Phramaceuticals has the most exposure, and Teva comes in second.) However, given the enormity of the drug makers' exposure, saying Amneal is the least exposed doesn't mean much.
If the litigation plays out in the generic drug makers' favor, Amneal will be a great stock available at bargain basement pricing. Until then, this stock is much too risky. It may continue to fall to its 1998 lows of under $1 per share.
S&P Capital IQ rates it an undervalued, high quality, and financially healthy company, but I think that overstates the case. In my opinion this company is at real financial risk. Amneal's cash reserve shrank by 3/4 year-over-year, while its accounts receivable grew in an equal amount. That suggests that while Amneal's assets may look good on paper, it may not be very liquid. Amneal may need to do a better job with collections. Furthermore, ongoing litigation over price fixing and the opioid epidemic exposes Amneal to potential damages of $1.2 billion, almost its total current assets.
Amneal has some support at its current share price as it approaches lows from back in 2008 and 2002-2003. It also got an analyst upgrade today from SVB Leerink after the analytics firm determined that of the major generic drug makers, Amneal has the least exposure to that ongoing litigation I mentioned. (Endo Phramaceuticals has the most exposure, and Teva comes in second.) However, given the enormity of the drug makers' exposure, saying Amneal is the least exposed doesn't mean much.
If the litigation plays out in the generic drug makers' favor, Amneal will be a great stock available at bargain basement pricing. Until then, this stock is much too risky. It may continue to fall to its 1998 lows of under $1 per share.